Skip to content

ARA-290

Also called Cibinetide

Non-erythropoietic EPO-derived peptide that activates the innate repair receptor.

  • TypePeptide
  • FormInjectable
  • Researched forHealing & Recovery

Where to get ARA-290

Flawless Compounds
Injectable
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop injectable at Flawless Compounds

The short version

  • Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
  • What the evidence isGenuine randomized human trials — ARA-290 (cibinetide) was studied in sarcoidosis-associated small-fiber neuropathy and in type 2 diabetic neuropathy.
  • What to watchBlood pressure creeping up or new pounding headaches.

How ARA-290 works

Non-erythropoietic EPO-derived peptide that activates the innate repair receptor — anti-inflammatory and nerve-repair without raising red cells.

ARA 290 is eleven amino acids cut out of the tertiary structure of erythropoietin, and the entire point of it is a receptor it does not hit. The sequence is pyroglutamate followed by Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser — a stretch of erythropoietin’s helix B that faces away from the surface EPO uses to bind its own receptor.

The receptor distinction is the drug. Erythropoietin acts through two different receptor assemblies. The EPOR homodimer drives erythropoiesis — that is the receptor that makes red cells and raises hematocrit.

  • Injectable

On the goal map: Satellite cells & local repair (Build muscle & strength)

Research on ARA-2905 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Human trials (neuropathy).

Human clinical evidence

  • Genuine randomized human trials — ARA-290 (cibinetide) was studied in sarcoidosis-associated small-fiber neuropathy and in type 2 diabetic neuropathy. In the largest trial (64 patients, 28 days), cibinetide significantly increased corneal nerve fiber area versus placebo (P = 0.012). Pain fell, but not significantly more than on placebo (P = 0.157).

  • Development did not continue to approval. That is a funding and commercial outcome, not a refutation — the neuropathy signal was one of the more promising in a field with very little that works.

Correlative data

  • Small but consistent community use for neuropathic pain and inflammation, where reported experience tracks the trials — slow-building relief over weeks rather than an acute effect.

How the mechanism reads

  • An 11-amino-acid peptide derived from erythropoietin's helix B — it binds the innate repair receptor (EPOR/βcR heterodimer) rather than the classical EPO receptor.

    Mechanistic
  • That receptor split is the entire design: it delivers EPO's tissue-protective and anti-inflammatory signaling without raising hematocrit, which is what makes EPO itself unusable for this purpose.

    Mechanistic

Sources

  • Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine 2015 · PMID 25387363
  • Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain 2014 · PMID 24529189
  • Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine 2020 · PMID 32674280
  • Nairz M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific Reports 2017 · PMID 29026145
  • Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482

ARA-290 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Active cancer, since tissue-protective EPO-receptor signaling is also used by tumor cells.
  • History of blood clots or an already high hematocrit.
  • Uncontrolled hypertension, a known erythropoietin-class concern.
  • Pregnancy or breastfeeding, which no trial covered.

What’s expected

  • Neuropathic pain and nerve-fiber signs improve gradually in diabetic and sarcoidosis neuropathy trials.
  • Lower inflammatory tone without extra red blood cells.
  • Transient site reactions or headache.

Watch for

  • Blood pressure creeping up or new pounding headaches.
  • One calf that swells, aches or turns red.
  • Hematocrit climbing on a routine test.

Labs that tell you it’s working

  • Complete Blood Count: hematocrit and hemoglobin should NOT rise, which is the design test for this molecule.
  • hs-CRP: shows whether the innate repair receptor dampens inflammation.
  • HbA1c: the neuropathy trials enrolled people with diabetes.

Non-erythropoietic EPO-derived helix B peptide that engages the EPOR/CD131 innate repair receptor, not the red-cell EPOR homodimer. PMID 32674280 PMID 25387363

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

ARA-290 FAQ4 common questions

Is ARA-290 approved for human use?
No. ARA-290 is a research compound.
What is ARA-290 researched for?
Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Which labs show whether it's doing anything?
Complete Blood Count; hs-CRP; HbA1c: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for ARA-290: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what ARA-290 is. Skool covers how it is run.

Free on this page

What ARA-290 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What ARA-290 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The ARA-290 lesson: the protocol, step by step, with Cam's video
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool